Consolidation and change throughout the biopharma industry has left many biotech firms without a development partner—or with a very different one. Some, like UCB Celltech , have been faced with an important asset thrown back into their lap; others have had to deal with the change associated with a new partner's needs and priorities.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?